Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 10 Nov 2015
Price : $35 *
At a glance
- Drugs Oprozomib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Onyx Pharmaceuticals
- 04 Nov 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 24 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 29 Apr 2015 Planned number of patients changed from 124 to 140 as reported by ClinicalTrials.gov record.